264 related articles for article (PubMed ID: 22606345)
1. Gene expression profiling of liver cancer stem cells by RNA-sequencing.
Ho DW; Yang ZF; Yi K; Lam CT; Ng MN; Yu WC; Lau J; Wan T; Wang X; Yan Z; Liu H; Zhang Y; Fan ST
PLoS One; 2012; 7(5):e37159. PubMed ID: 22606345
[TBL] [Abstract][Full Text] [Related]
2. miR-589-5p inhibits MAP3K8 and suppresses CD90
Zhang X; Jiang P; Shuai L; Chen K; Li Z; Zhang Y; Jiang Y; Li X
J Exp Clin Cancer Res; 2016 Nov; 35(1):176. PubMed ID: 27835990
[TBL] [Abstract][Full Text] [Related]
3. Discrete nature of EpCAM+ and CD90+ cancer stem cells in human hepatocellular carcinoma.
Yamashita T; Honda M; Nakamoto Y; Baba M; Nio K; Hara Y; Zeng SS; Hayashi T; Kondo M; Takatori H; Yamashita T; Mizukoshi E; Ikeda H; Zen Y; Takamura H; Wang XW; Kaneko S
Hepatology; 2013 Apr; 57(4):1484-97. PubMed ID: 23174907
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib suppresses extrahepatic metastasis de novo in hepatocellular carcinoma through inhibition of mesenchymal cancer stem cells characterized by the expression of CD90.
Yoshida M; Yamashita T; Okada H; Oishi N; Nio K; Hayashi T; Nomura Y; Hayashi T; Asahina Y; Ohwada M; Sunagozaka H; Takatori H; Colombo F; Porretti L; Honda M; Kaneko S
Sci Rep; 2017 Sep; 7(1):11292. PubMed ID: 28900199
[TBL] [Abstract][Full Text] [Related]
5. The prognostic value of combination of CD90 and OCT4 for hepatocellular carcinoma after curative resection.
Zhao RC; Zhou J; Chen KF; Gong J; Liu J; He JY; Guan P; Li B; Qin Y
Neoplasma; 2016; 63(2):288-98. PubMed ID: 26674131
[TBL] [Abstract][Full Text] [Related]
6. Positive correlation of Oct4 and ABCG2 to chemotherapeutic resistance in CD90(+)CD133(+) liver cancer stem cells.
Jia Q; Zhang X; Deng T; Gao J
Cell Reprogram; 2013 Apr; 15(2):143-50. PubMed ID: 23438193
[TBL] [Abstract][Full Text] [Related]
7. HOXA-AS2 Promotes Proliferation and Induces Epithelial-Mesenchymal Transition via the miR-520c-3p/GPC3 Axis in Hepatocellular Carcinoma.
Zhang Y; Xu J; Zhang S; An J; Zhang J; Huang J; Jin Y
Cell Physiol Biochem; 2018; 50(6):2124-2138. PubMed ID: 30415263
[TBL] [Abstract][Full Text] [Related]
8. The Notch pathway promotes the cancer stem cell characteristics of CD90+ cells in hepatocellular carcinoma.
Luo J; Wang P; Wang R; Wang J; Liu M; Xiong S; Li Y; Cheng B
Oncotarget; 2016 Feb; 7(8):9525-37. PubMed ID: 26848615
[TBL] [Abstract][Full Text] [Related]
9. ZHX2 restricts hepatocellular carcinoma by suppressing stem cell-like traits through KDM2A-mediated H3K36 demethylation.
Lin Q; Wu Z; Yue X; Yu X; Wang Z; Song X; Xu L; He Y; Ge Y; Tan S; Wang T; Song H; Yuan D; Gong Y; Gao L; Liang X; Ma C
EBioMedicine; 2020 Mar; 53():102676. PubMed ID: 32114388
[TBL] [Abstract][Full Text] [Related]
10. The expression of CD90/Thy-1 in hepatocellular carcinoma: an in vivo and in vitro study.
Sukowati CH; Anfuso B; Torre G; Francalanci P; Crocè LS; Tiribelli C
PLoS One; 2013; 8(10):e76830. PubMed ID: 24116172
[TBL] [Abstract][Full Text] [Related]
11. Reduced nucleic ZHX2 involves in oncogenic activation of glypican 3 in human hepatocellular carcinoma.
Luan F; Liu P; Ma H; Yue X; Liu J; Gao L; Liang X; Ma C
Int J Biochem Cell Biol; 2014 Oct; 55():129-35. PubMed ID: 25195714
[TBL] [Abstract][Full Text] [Related]
12. Recurrence and poor prognosis following resection of small hepatitis B-related hepatocellular carcinoma lesions are associated with aberrant tumor expression profiles of glypican 3 and osteopontin.
Yu MC; Lee YS; Lin SE; Wu HY; Chen TC; Lee WC; Chen MF; Tsai CN
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S455-63. PubMed ID: 21822558
[TBL] [Abstract][Full Text] [Related]
13. Significance of CD90+ cancer stem cells in human liver cancer.
Yang ZF; Ho DW; Ng MN; Lau CK; Yu WC; Ngai P; Chu PW; Lam CT; Poon RT; Fan ST
Cancer Cell; 2008 Feb; 13(2):153-66. PubMed ID: 18242515
[TBL] [Abstract][Full Text] [Related]
14. miR-125a/b inhibits tumor-associated macrophages mediated in cancer stem cells of hepatocellular carcinoma by targeting CD90.
Wang Y; Wang B; Xiao S; Li Y; Chen Q
J Cell Biochem; 2019 Mar; 120(3):3046-3055. PubMed ID: 30536969
[TBL] [Abstract][Full Text] [Related]
15. Long noncoding RNA glypican 3 (GPC3) antisense transcript 1 promotes hepatocellular carcinoma progression via epigenetically activating GPC3.
Zhu XT; Yuan JH; Zhu TT; Li YY; Cheng XY
FEBS J; 2016 Oct; 283(20):3739-3754. PubMed ID: 27573079
[TBL] [Abstract][Full Text] [Related]
16. Identification of local and circulating cancer stem cells in human liver cancer.
Yang ZF; Ngai P; Ho DW; Yu WC; Ng MN; Lau CK; Li ML; Tam KH; Lam CT; Poon RT; Fan ST
Hepatology; 2008 Mar; 47(3):919-28. PubMed ID: 18275073
[TBL] [Abstract][Full Text] [Related]
17. Circulating tumor and cancer stem cells in hepatitis C virus-associated liver disease.
Bahnassy AA; Zekri AR; El-Bastawisy A; Fawzy A; Shetta M; Hussein N; Omran D; Ahmed AA; El-Labbody SS
World J Gastroenterol; 2014 Dec; 20(48):18240-8. PubMed ID: 25561791
[TBL] [Abstract][Full Text] [Related]
18. Gene expression profiling of MYC-driven tumor signatures in porcine liver stem cells by transcriptome sequencing.
Aravalli RN; Talbot NC; Steer CJ
World J Gastroenterol; 2015 Feb; 21(7):2011-29. PubMed ID: 25717234
[TBL] [Abstract][Full Text] [Related]
19. T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in Mice.
Dargel C; Bassani-Sternberg M; Hasreiter J; Zani F; Bockmann JH; Thiele F; Bohne F; Wisskirchen K; Wilde S; Sprinzl MF; Schendel DJ; Krackhardt AM; Uckert W; Wohlleber D; Schiemann M; Stemmer K; Heikenwälder M; Busch DH; Richter G; Mann M; Protzer U
Gastroenterology; 2015 Oct; 149(4):1042-52. PubMed ID: 26052074
[TBL] [Abstract][Full Text] [Related]
20. New tumor suppressor microRNAs target glypican-3 in human liver cancer.
Cartier F; Indersie E; Lesjean S; Charpentier J; Hooks KB; Ghousein A; Desplat A; Dugot-Senant N; Trézéguet V; Sagliocco F; Hagedorn M; Grosset CF
Oncotarget; 2017 Jun; 8(25):41211-41226. PubMed ID: 28476031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
